OncoTherapy Science, Inc. (TYO:4564)

Market Cap	6.34B
Revenue (ttm)	707.00M
Net Income (ttm)	-1.02B
Shares Out	275.64M
EPS (ttm)	-4.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,100,300
Average Volume	2,330,310
Open	23.00
Previous Close	24.00
Day's Range	23.00 - 24.00
52-Week Range	15.00 - 64.00
Beta	0.19
RSI	42.07
Earnings Date	May 9, 2025

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 54
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4564

Financial Performance

In 2023, OncoTherapy Science's revenue was 610.00 million, a decrease of -46.21% compared to the previous year's 1.13 billion. Losses were -1.29 billion, 15.2% more than in 2022.